Catalent, Inc. (NYSE:CTLT) Receives $55.65 Average PT from Brokerages

Shares of Catalent, Inc. (NYSE:CTLT) have received a consensus recommendation of “Hold” from the eleven ratings firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and three have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $55.65.

Several research analysts have issued reports on CTLT shares. Royal Bank of Canada restated a “sector perform” rating and set a $63.50 target price on shares of Catalent in a research report on Thursday, July 11th. Barclays lifted their price target on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research note on Friday, June 28th. Finally, StockNews.com initiated coverage on shares of Catalent in a research note on Thursday. They set a “sell” rating for the company.

Insider Buying and Selling

In related news, CEO Alessandro Maselli sold 9,088 shares of the business’s stock in a transaction that occurred on Monday, July 29th. The shares were sold at an average price of $58.76, for a total value of $534,010.88. Following the completion of the transaction, the chief executive officer now owns 177,521 shares of the company’s stock, valued at $10,431,133.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Catalent news, CFO Matti Masanovich sold 2,993 shares of Catalent stock in a transaction on Monday, July 8th. The shares were sold at an average price of $56.74, for a total value of $169,822.82. Following the transaction, the chief financial officer now directly owns 33,871 shares of the company’s stock, valued at $1,921,840.54. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction on Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the completion of the transaction, the chief executive officer now directly owns 177,521 shares in the company, valued at $10,431,133.96. The disclosure for this sale can be found here. Insiders sold 13,482 shares of company stock valued at $779,852 over the last 90 days. Corporate insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Catalent

Several institutional investors and hedge funds have recently bought and sold shares of CTLT. Nomura Holdings Inc. grew its holdings in Catalent by 149.4% in the fourth quarter. Nomura Holdings Inc. now owns 11,487,342 shares of the company’s stock worth $516,126,000 after purchasing an additional 6,881,914 shares during the last quarter. Norges Bank purchased a new stake in shares of Catalent during the fourth quarter valued at $116,021,000. Capital World Investors increased its position in shares of Catalent by 6.1% in the 4th quarter. Capital World Investors now owns 19,079,994 shares of the company’s stock valued at $857,264,000 after acquiring an additional 1,098,474 shares during the period. Magnetar Financial LLC acquired a new position in shares of Catalent in the 1st quarter valued at $56,429,000. Finally, Cadian Capital Management LP increased its position in shares of Catalent by 14.3% in the 4th quarter. Cadian Capital Management LP now owns 6,064,384 shares of the company’s stock valued at $272,473,000 after acquiring an additional 759,600 shares during the period.

Catalent Stock Down 0.3 %

Shares of NYSE:CTLT opened at $59.59 on Tuesday. Catalent has a 1 year low of $31.80 and a 1 year high of $60.20. The business has a 50 day simple moving average of $56.66 and a two-hundred day simple moving average of $56.03. The firm has a market capitalization of $10.78 billion, a PE ratio of -9.77, a price-to-earnings-growth ratio of 2.47 and a beta of 1.16. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.77.

Catalent (NYSE:CTLT) last announced its earnings results on Wednesday, May 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.21 by ($0.36). Catalent had a negative net margin of 26.61% and a negative return on equity of 2.73%. The business had revenue of $1.07 billion for the quarter, compared to analysts’ expectations of $1.11 billion. On average, equities analysts predict that Catalent will post -0.17 EPS for the current year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.